DPP4抑制剂在2型糖尿病中的临床应用及研究进展

Clinical Application and Research Progress of DPP4 Inhibitors in 2 Diabetes

2型糖尿病(Type 2 Diabetes Mellitus,T2DM)在我国具有较高的发病率,是中老年患者常见的一种慢性代谢疾病,可累及心脑血管等多个系统发生病变,危及生命安全,需及时治疗。二肽基肽酶-4(Dipeptidyl Peptidase-4,DPP4)可促进胰岛素生成,并分泌胰高血糖素,与T2DM有着密切关联,是目前我国T2DM治疗研究中的一个新方向。DPP4抑制剂是多项研究的结果,能够提高降糖效果,对多种降糖无效的患者均有显著作用。基于此,本文主要综述了DPP4抑制剂治疗T2DM的作用机制,分析DPP4抑制剂在T2DM中的应用及研究进展,以期为T2DM治疗提供参考。

Type 2 diabetes mellitus(T2DM)has a high incidence rate in my country and is a common chronic metabolic disease in middle-aged and elderly patients.It can involve multiple systems such as the cardiovascular and cerebrovascular systems,endangering life and requiring prompt treatment.Dipeptidyl peptidase-4(DPP4)can promote insulin production and secrete glucagon.It is closely related to T2DM and is a new direction in the current research on T2DM treatment in my country.DPP4 inhibitors are the results of multiple studies and can improve the blood glucose-lowering effect and have significant effects on a variety of patients who are ineffective in lowering blood glucose.Based on this,this article mainly reviews the mechanism of action of DPP4 inhibitors in the treatment of T2DM,analyzes the application and research progress of DPP4 inhibitors in T2DM,in order to provide reference for the treatment of T2DM.